Skip to main content

Table 1 Patient clinicopathological characteristics and correlation with rad-CD73

From: Radiomics using computed tomography to predict CD73 expression and prognosis of colorectal cancer liver metastases

Variable

All dataset

(N = 122)

rad-CD73High (n = 79)

rad-CD73Low (n = 43)

p-value

Age at hepatectomy (Mean, range)

(63.4, 35–84)

(63.6, 35–84)

(63.2, 44–81)

0.894

 ≤ 65 years

66 (54.1)

42 (53.2)

24 (55.8)

 

 > 65 years

56 (45.9)

37 (46.8)

19 (44.2)

 

Gender

0.430

 Male

78 (63.9)

48 (60.8)

30 (69.8)

 

 Female

44 (36.1)

31 (39.2)

13 (30.2)

 

Number of metastases (Mean, range)

(2.0, 1–10)

(2.1, 1–10)

(1.9, 1–5)

0.643

 Single

59 (48.4)

41 (51.9)

18 (41.9)

 

 Multiple

63 (51.6)

38 (48.1)

25 (58.1)

 

Diameter of largest metastasis (Mean, range)

(4.1, 1.0–20.0)

(4.3, 1.0–20.0)

(3.8, 1.3–11.0)

0.830

 ≤ 5 cm

93 (76.2)

59 (74.7)

34 (79.1)

 

 > 5 cm

29 (23.8)

20 (25.3)

9 (20.9)

 

KRAS status

0.735

 Wild-type

27 (61.4)

18 (58.1)

9 (69.2)

 

 Mutated

17 (38.6)

13 (41.9)

4 (30.8)

 

CEA level

0.287

 ≤ 200 ng/mL

118 (97.5)

77 (98.7)

41 (95.3)

 

 > 200 ng/mL

3 (2.5)

1 (1.3)

2 (4.7)

 

Clinical risk scorea

0.017

 Low risk (0–2)

72 (61.5)

53 (69.7)

19 (46.3)

 

 High risk (3–5)

45 (38.5)

23 (30.3)

22 (53.7)

 

Margin liver resection

0.325

 Negative

111 (91.0)

70 (88.6)

41 (95.3)

 

 Positive

11 (9.0)

9 (11.4)

2 (4.7)

 

Tertiary lymphoid structure

0.775

 No

107 (87.7)

70 (88.6)

37 (86.0)

 

 Yes

15 (12.3)

9 (11.4)

6 (14.0)

 

Necrosis (Mean, range)

(12.3, 0.0–81.5)

(13.2, 0–81.5)

(10.7, 0.0–61.8)

0.358

 ≤ 25%

104 (85.2)

67 (84.8)

37 (86.0)

 

 > 25%

18 (14.8)

12 (15.2)

6 (14.0)

 

Primary tumor

0.140

 Left sided

82 (69.5)

58 (74.4)

24 (60.0)

 

 Right sided

36 (30.5)

20 (25.6)

16 (40.0)

 

pT category

0.190

 pT1-pT3

93 (83.0)

56 (78.9)

37 (90.2)

 

 pT4

19 (17.0)

15 (21.1)

4 (9.8)

 

pN category

0.116

 pN0

43 (35.8)

32 (41.0)

11 (26.2)

 

 pN + 

77 (64.2)

46 (59.0)

31 (73.8)

 

Preop chemotherapy

1.000

 No

26 (21.3)

17 (21.5)

9 (20.9)

 

 Yes

96 (78.7)

62 (78.5)

34 (79.1)

 

Tumor regression gradeb

0.575

 1–2

16 (13.1)

9 (11.4)

7 (16.3)

 

 3–4–5

106 (86.9)

70 (88.6)

36 (83.7)

 

Extrahepatic recurrence

0.806

 No

32 (36.0)

24 (37.5)

8 (32.0)

 

 Yes

57 (64.0)

40 (62.5)

17 (68.0)

 

Disease-free interval between primary and liver met

 

 < 12 months

88 (72.1)

52 (65.8)

36 (83.7)

0.037

 ≥ 12 months

34 (27.9)

27 (34.2)

7 (16.3)

 
  1. CEA carcinoembryonic antigen, CD cluster of differentiation, T tumor, N node
  2. aClinical Risk Score calculated by the addition of one point for the following features: disease-free interval between the diagnosis of primary tumor and liver metastases < 12 months; number of metastases > 1; pre-operative CEA level > 200 ng/mL; largest metastasis > 5 cm; and lymph node positive primary tumor[19]
  3. bMeasure of histopathological response to neoadjuvant chemotherapy as defined by Rubbia-Brandt et al.[20]
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us